- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01492335
Cognitive Assessment of Elderly Primary Care Patients
January 13, 2016 updated by: University of Pittsburgh
Most primary care physicians do not screen older patients for cognitive impairment.
Identification of cognitive impairment may result in earlier referral for diagnostic work-up and earlier treatment and better patient outcomes.
The purpose of this study is to determine whether physicians who receive the results of a cognitive screen use this information in treatment plans and whether this results in better cognitive outcomes for the older patients.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Current trends in healthcare suggest that in the coming decade most older patients will obtain services solely through the general practice/family practice sector of healthcare.
Effective and optimal management of older patients with multiple complex medical conditions and compromised cognitive functioning will be a challenge for the primary care physician (PCP).
Early identification of older patients with cognitive deficits should allow early referral for diagnostic work-up and earlier treatment and better patient outcomes.
The goal of this study is to investigate the utility of providing cognitive testing in the PCP office.
PCPs will be randomized to either Treatment As Usual (TAU) or Cognitive Report (CR).
The study hypotheses are (1) patients of physicians in the CR group will have improved clinical outcomes i.e. cognitively impaired patients in the CR group will have a slower rate of progression of cognitive deficits over two years than cognitively impaired patients in the TAU group; (2) PCPs in the CR group will order dementia screening tests, refer to specialists and prescribe anticholinesterase inhibitors more frequently than PCPs in the TAU group.
Study Type
Interventional
Enrollment (Actual)
524
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- University of Pittsburgh
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
65 years and older (Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age 65 or over
- Plan to remain a patient of this physician for two years
- MMSE score greater than 18
Exclusion Criteria:
- Diagnosis of Dementia, Alzheimer's disease, Huntington's disease, Vascular disease or other dementing disorder
- MMSE score of 18 or less
- Sensory deficit e.g. limited vision or hearing precluding cognitive testing
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Cognitive Report
Primary care physicians in the Cognitive Report group receive the results of their patients cognitive testing together with clinical diagnosis (Normal, Mild Cognitive Impairment, Dementia) and treatment recommendations.
|
Physicians in the Cognitive Report group receive the results of their patients cognitive assessment which includes a clinical diagnosis (Normal, Mild Cognitive Impairment, Dementia) and treatment recommendations
|
|
Experimental: Treatment As Usual
Physicians in the Treatment As Usual Group do not receive the results of their patients cognitive assessment, they do not receive treatment recommendations, nor are they told of the patients diagnosis (Normal, Mild Cognitive Impairment, Dementia)
|
Physicians in the Treatment As Usual group do not receive the results of their patients cognitive assessments, they are not given treatment recommendations nor are they told of the patients clinical diagnosis (Normal, Mild Cognitive Impairment, Dementia).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Scores on a comprehensive battery of neuropsychological tests.
Time Frame: Two years
|
Diagnosis is based on performance on a standard neuropsychological test battery that assesses mutliple cognitive domains known to be sensitive to early dementia.
|
Two years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Judith Saxton, PhD, University of Pittsburgh
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2006
Primary Completion (Actual)
October 1, 2011
Study Completion (Actual)
August 1, 2012
Study Registration Dates
First Submitted
December 2, 2011
First Submitted That Met QC Criteria
December 13, 2011
First Posted (Estimate)
December 14, 2011
Study Record Updates
Last Update Posted (Estimate)
January 14, 2016
Last Update Submitted That Met QC Criteria
January 13, 2016
Last Verified
January 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PCP-AG023129
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mild Cognitive Impairment
-
Saglik Bilimleri UniversitesiAnkara UniversityRecruitingAmnestic Mild Cognitive Impairment | Amnestic Mild Cognitive DisorderTurkey
-
Masaryk UniversityRecruitingMild Cognitive Impairment (MCI) Amnestic | Lewy Body Disease With Mild Cognitive Impairment | Parkinson's Disease With Mild Cognitive ImpairmentCzechia
-
High Point UniversityWake Forest University Health Sciences; Hebrew SeniorLifeRecruitingMild Cognitive Impairment (MCI)United States
-
Azienda Ospedaliera SS. Antonio e Biagio e Cesare...Dr. Schär AG / SPARecruitingMild Cognitive Impairment (MCI)Italy
-
Xuanwu Hospital, BeijingWuhan University; Beijing Friendship Hospital; First Affiliated Hospital Xi'an... and other collaboratorsRecruitingAmnestic Mild Cognitive ImpairmentChina
-
Immunotec Inc.RecruitingMild Cognitive Impairment (MCI)Canada
-
Çankırı Karatekin UniversityCompletedMild Cognitive Impairment (MCI)Turkey (Türkiye)
-
University of AlbertaCompleted
-
Friedhelm HummelThe Novartis Foundation; Wyss Center for Bio and Neuroengineering; Clinique Romande... and other collaboratorsCompletedMild Cognitive Impairment (MCI)Switzerland
-
Jennifer BramenNational Institutes of Health (NIH); National Institute on Aging (NIA)TerminatedAmnestic Mild Cognitive ImpairmentUnited States
Clinical Trials on Cognitive Report
-
St. Jude Children's Research HospitalCompletedSickle Cell DiseaseUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
Memorial University of NewfoundlandCompletedUrinary Tract Infections | Asymptomatic BacteriuriaCanada
-
MYnd AnalyticsMount Sinai Hospital, New YorkSuspended
-
MYnd AnalyticsUniversity of Ottawa; Canadian Forces Health Services Centre OttawaUnknownDepression | Non-psychotic Diagnosis as Co-morbidityCanada
-
Shandong UniversityUnknown
-
Sunnybrook Health Sciences CentreCancer Care OntarioCompleted
-
CHU de Quebec-Universite LavalRecruitingProstate Cancer | Localized Prostate Carcinoma | Radiotherapy Side Effect | Radiotherapy | Brachytherapy | HypofractionationCanada
-
ImbioNational Cancer Institute (NCI); Mayo Clinic; University of Michigan; University... and other collaboratorsCompleted
-
Vanderbilt UniversityCompleted